Samsung DS faces challenges, with hope to recover in 2Q25
Samsung Electronics’ Device Solutions (DS) division has reported weaker-than-expected earnings for the fourth quarter of 2024, grappling with a series…
Nvidia faces challenges as DeepSeek disrupts AI market ahead of 1Q25 earnings
Nvidia’s stock value has declined sharply in recent days following the emergence of Chinese AI startup DeepSeek, resulting in a…
South Korean industry skeptical of DeepSeek’s AI cost claims
DeepSeek, a Chinese artificial intelligence (AI) startup, has stirred industry discussion with the announcement of its new “high-efficiency AI” model.…
US and Canada agree to 30-day pause on tariffs
The two countries will push back a Feb. 4 enforcement date as they coordinate anti-drug trafficking efforts at their shared…
S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals
International Council on Harmonisation – Safety
E7 Studies in Support of Special Populations; Geriatrics; Questions and Answers
International Council on Harmonisation – Efficacy
Gingivitis: Development and Evaluation of Drugs for Treatment or Prevention
Clinical / Medical
FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND: Frequently Asked Questions
Guidance for Industry and FDA Staff: FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND; Frequently Asked Questions
